Over the past two decades, anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line biologic treatment to treat moderate-to-severe IBD in both “step up” and “top down” approaches. The gene discussed is TNF; the disease is irritable bowel syndrome.